Cellectar adopts amended bylaws and indemnification agreements for directors and officers

Cellectar Biosciences, Inc.

Bylaws amended to include exclusive forum provision and clarify director removal only for cause with majority vote.
Special meetings of stockholders and stockholder proposals subject to enhanced procedural mechanics.
Indemnification agreements with each director and executive officer provide full indemnity to extent permitted by Delaware law.
Company also updated bylaws to reflect current name, DGCL updates, and emergency procedures under Section 110.
No financial or operational changes reported; governance-only filing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cellectar Biosciences, Inc.: Amended and restated by-laws to reflect name change, enhance stockholder meeting mechanics, add director nomination requirements, clarify board procedures, and make other updates (effective 2022-11-29).

Change: bylaw amendment
Effective: 2022-11-29

Exact text from the filing

On November 29, 2022, the board of directors (the “ Board ”) of the Company adopted the Amended and Restated By-Laws of the Company (the “ By-Laws ”), effective immediately.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-124193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.